XTL Biopharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw 4th Annual Global Health Care Conference
09 May 2007 - 7:35PM
PR Newswire (US)
VALLEY COTTAGE, New York, May 9 /PRNewswire-FirstCall/ -- XTL
Biopharmaceuticals Ltd. (NASDAQ:XTLB)(LSE:XTL)(TASE:XTL) announced
today that Ram Waisbourd, the Company's Vice President of Business
Development, is scheduled to present at the Acumen BioFin Rodman
& Renshaw 4th Annual Global Health Care Conference
(http://www.rodmanandrenshaw.com/eu07conference). Mr. Waisbourd
will present an overview of the Company including an overview of
Bicifadine, the Company's recently in-licensed late-stage clinical
compound for the treatment of neuropathic pain. Mr. Waisbourd's
presentation will take place on Tuesday, May 15, 2007, at 8:40am
local time in Monte Carlo (2:40am Eastern Daylight Time and 9:40am
Israel Daylight Time), at the Le Meridien Beach Plaza Hotel in
Monte Carlo, Monaco. A live audio webcast of Mr. Waisbourd's
presentation will be available at:
http://www.wsw.com/webcast/rrshq11/xtlb. An archived version of the
webcast will be available following the conclusion of the live
presentation. About XTL Biopharmaceuticals Ltd. XTL
Biopharmaceuticals Ltd. ("XTL") is engaged in the acquisition,
development and commercialization of therapeutics for the treatment
of neuropathic pain and hepatitis C. XTL is developing Bicifadine,
a serotonin and norepinephrine reuptake inhibitor, for the
treatment of neuropathic pain. In addition, XTL is developing
XTL-2125 - a small molecule, non-nucleoside inhibitor of the
hepatitis C virus polymerase. XTL-2125 is currently in a Phase I
clinical trial in patients with chronic hepatitis C. XTL is also
developing XTL-6865 - a combination of two monoclonal antibodies
against the hepatitis C virus. XTL's hepatitis C pipeline also
includes several families of pre-clinical hepatitis C small
molecule inhibitors. XTL also has an active in-licensing and
acquisition program designed to identify and acquire additional
drug candidates. XTL is publicly traded on the NASDAQ, London, and
Tel-Aviv Stock Exchanges (NASDAQ:XTLB)(LSE:XTL)(TASE:XTL). Contact:
Ron Bentsur, Chief Executive Officer Tel: +1-845-267-0707 ext. 225
DATASOURCE: XTL Biopharmaceuticals Ltd CONTACT: Contact: Ron
Bentsur, Chief Executive Officer, Tel: +1-845-267-0707 ext. 225
Copyright
XTL Biopharmaceuticals (NASDAQ:XTLB)
Historical Stock Chart
From Jun 2024 to Jul 2024
XTL Biopharmaceuticals (NASDAQ:XTLB)
Historical Stock Chart
From Jul 2023 to Jul 2024